Galectin Therapeutics Inc. (GALT) key performance indicators and operating metrics (1 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Incidence of Esophageal Varices Reduction versus Placebo Per-Protocol | 49.30 percent | FY2025-Q1 |
Back to GALT overview · GALT earnings · GALT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.